STERIS plc

STE · NYSE · ·

比較

$253.57-1.1%11月12日終値

2026年9月30日までの数値（2026年11月5日提出の10-Qより）

1W: +0.5%
1M: +16.7%
3M: +8.9%

Just reported

Q2 FY2027 results

From STERIS's results release of 2026年11月4日; its quarterly report has since been filed.

Revenue
Actual
$1.59B
+8.8% y/y
+6.4% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
$294.3M
+11% y/y
+3.0% q/q
Guided
—
No guide given

Company outlook

Full year 2027

EPS, adjusted$11.35 – $11.55Raised +2.2%

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes STERIS is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The themes it is part of

キュレーション
Medical devices
InspectStocks 編集 · 20 companies
Surgical robots, implants, heart devices, glucose monitors and other medical equipment.
株価、1 年
+2.7%
売上、1 年
+7.2%
+14
A 8B 7C 3D 2

Highest-graded in Medical Devices

Graded A or B and worth $2B or more: A first, then the largest.

All 133 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

財務諸表をすべて見る →

STERIS plc 自身が米国証券取引委員会（SEC）に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。

STERIS plc

STERIS plc

Q2 FY2027 results

Revenue